OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← Pten Research Foundation

2024-03-31-accounts

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

Charity number: 1173589

Registered number: 10529899

PTEN RESEARCH FOUNDATION FINANCIAL STATEMENTS YEAR ENDED 31 MARCH 2024

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

CONTENTS

Page
Reference and administrative details of the Charity, its Trustees and advisers 1
Trustees' report 2-11
Independent auditors' report on the financial statements 12-14
Statement of financial activities 15
Balance sheet 16
Statement of cash flows 17
Notes to the financial statements 18-33

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION A company limited by guarantee

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS

FOR THE YEAR ENDED 31 MARCH 2024

Trustees/Directors Siriana Baldini Susannah Clark Renata Crome Robert Williams Riccardo Zacconi Company Registered Number 10529899 Charity Registered Number 1173589 Registered Office 4[th] Floor St James House Cheltenham GL50 3PR Independent auditors Crowe U.K. LLP 4[th] Floor St James House Cheltenham GL50 3PR Investment Manager Brown Advisory 18 Hanover Square London, W1S 1JY Bankers Barclays Wealth Mayfair London W1K 1AF JP Morgan SE 6 Route de Treves L-2633 Senningerberg Luxembourg

Page 1

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

The Trustees, who are also Directors for the purposes of Company Law, present their annual report together with the audited financial statements of the charity for the year 1st April 2023 to 31st March 2024. The Trustees confirm that the Annual Report and financial statements of the company comply with current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Trustees

The Trustees who served during the period were:

Siriana Baldini Susannah Clark Renata Crome Robert Williams Riccardo Zacconi

Riccardo Zacconi has signed the report on behalf of the Board of Trustees and the Directors.

Members

The company currently has a single member, Blue Compass PTC Limited, which has been in place since 16[th] December 2016.

Structure, governance and management

1. Name of the governing document and how the charity is constituted

The PTEN Research Foundation ('the Foundation' or 'PTEN Research') was established as a charity under English and Welsh law in 2017 (registered number 1173589). The Foundation is constituted under a Memorandum of Association and Articles of Association, dated 16[th] December 2016, which were revised by a special resolution of the Foundation’s member on 18[th] July 2022 (the ‘Revised Articles’). The Foundation's mission is to fund and facilitate research that will lead to better treatments and improved outcomes for PTEN hamartoma tumour syndrome (‘PHTS’).

2. Methods used to recruit and appoint new trustees

Under the Revised Articles, PTEN Research must have not less than three Trustees and unless and until the Charity determines otherwise by ordinary resolution, the number of its Trustees is not subject to a maximum limit.

The appointment, recruitment, and terms of office of Trustees are determined by the governance needs of the Foundation to meet its mission. New Trustees are recruited through relevant scientific, research or business networks. Active consideration is given to the diversity of the Board. Any person who is willing to act as a Trustee and is permitted by law to do so, may be appointed by an ordinary resolution of the member. To date Trustees have been appointed based on their skills and knowledge, and the contribution they can offer the Foundation.

3. The charity’s organisational structure and how decisions are made

The organisational structure of the Foundation is as follows:

Page 2

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

daily running of the Foundation. Under the Revised Articles, decisions of the Board must be supported by a majority of the Trustees either in person or in writing. The Trustees and member can exercise the powers of the charity as described in the published Revised Articles. As at 31st March 2024, and as at the date of this report, the Foundation's Board of Trustees included five individuals with knowledge in the fields of drug development, finance, communications, law and business development. The Trustees meet at least four times a year.

The Foundation has a small team of staff who have the delegated authority to oversee the day-to-day running of the charity, ensuring that it adheres to its charitable objectives and mission.

At 31st March 2024, the Scientific Advisory Board (the ‘SAB’) comprised ten experts whose specialisms included: medicine and genetics, scientific research including specifically drug development, and clinical research. The SAB meets on average once a year to discuss the scientific progress of the Foundation. The SAB is also consulted during the year to advise on grants or to give input into scientific projects. SAB members have an advisory role and no decision-making authority.

4. Policies and procedures for induction and training of trustees

On appointment, new Trustees sign a trustee declaration statement committing their time and expertise to the Foundation. After an initial meeting at which new trustees meet the Foundation’s staff, they are introduced to the Foundation’s grant making process, policies and procedures, and other relevant activities. New trustees are given access to the Foundation's governing documents, HR policies, financial information, annual reports and accounts, meeting materials and essential trustee guidance provided by the Charity Commission. In May and June 2022, Trustees were provided with two training modules commissioned from an external consultant, which covered trustees’ duties and responsibilities as required by law and best practice. In Autumn 2023, a selfreflection questionnaire was completed individually by all Trustees and results were discussed by the Board. covering leadership and governance, relationships with staff, delivery of goals, attitude to risk, skills and capabilities, behaviours, diversity and support from staff. Areas for improvement were identified, notably in the area of succession planning, which has now been built into staff annual reviews.

5. Arrangements for setting pay and remuneration of key management personnel

Trustees are not remunerated for their work. Trustee expenses are reimbursed in line with Foundation policy. Pay and remuneration of key management staff is set by the trustees after a review of relevant market data. Key management staff comprise the Chief Executive/Director of Clinical Development (combined role), the Director of Translational Medicine and the Director of Finance and Business Operations. Staff pay and remuneration are reviewed annually.

6. The Charities (Protection and Social Investment) Act 2016

The Foundation is a larger charity as defined by S144(2) of the Charities Act 2011. As such, under The Charities (Protection and Social Investment) Act 2016, it must provide information and undertakings in respect of fundraising activities carried out during the period under review in its trustees’ report. During the year ended 31st March 2024, the Foundation did not engage a professional fundraiser or commercial participator or any other person to raise funds on its behalf; neither the Foundation nor anyone acting on its behalf was subject to an undertaking to be bound by any voluntary scheme for regulating fund-raising, or any voluntary standard of fundraising; and no complaints were received by the Foundation or any person acting on its behalf about fund raising activities. The Foundation’s website states that volunteers are not authorised to raise funds on its behalf, and that volunteers who choose to raise funds in aid of the Foundation are solely responsible for all aspects of those activities, for which the Foundation has no liability. The Foundation’s website encourages ‘in aid of’ fundraisers to act within the law.

Objectives and Activities

1. Purposes of the charity and strategy

Under its governing documents, the Foundation's purposes are specifically restricted to: "the protection and promotion of the health of individuals diagnosed with PTEN hamartoma tumour syndrome (PHTS) or other related conditions (by mechanism, clinical presentation or other factors) in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of PHTS or other related conditions, including the development of findings of research into practical applications for the prevention, treatment and cure of PHTS or other related

Page 3

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

conditions, and in furtherance of that primary object, to increase awareness of PHTS or other related conditions and provide information and support as appropriate to affected individuals and families; and all purposes that are of public benefit and are exclusively charitable under the law of England and Wales."

PHTS is a rare genetic disease caused by alteration (mutation) to the PTEN gene. These alterations may be inherited from the mother or father, or they may occur spontaneously during embryonic development. They result in a variety of symptoms and signs, including macrocephaly (enlarged head circumference), learning difficulties, autism spectrum disorder, vascular (blood vessel) anomalies, gastrointestinal polyps (growths in the gut), and hamartomas (benign lesions of the skin and other tissues). In addition, people with PHTS have a significantly increased lifetime risk of developing cancer, particularly cancers of the breast, thyroid, and endometrium (lining of the womb).

Due to its variable presentation, the true prevalence of PHTS in the general population is not known but is estimated to be about 1 in 200,000 [1]; however, more recent studies based on the prevalence of PTEN mutations in ASD suggest the prevalence of PHTS may be significantly higher. In a recent large study with sequencing data from 5,100 individuals with ASD, PTEN was one of the most common genes with ASD associated rare variants [2] and based on a meta-analysis of 9 studies [3] it has been estimated that 2% of individuals with ASD harbour a PTEN germline mutation [4].

There are currently no health-authority-approved treatments specific to PHTS, and clinical management of people with PHTS is largely focused on cancer surveillance and supportive care, which are associated with a high burden on healthcare systems. Consequently, there is a high unmet need for therapies to treat or even prevent the development of the various symptoms associated with PHTS, as well as to improve the understanding of the syndrome to enable more accurate prognosis and improved management for diagnosed individuals. Developing therapies which mitigate the high burden on health systems is therefore for the wider public benefit.

The Foundation’s strategy centres on the generation of preclinical and clinical evidence that will enable the Foundation, and others (both academic collaborators and industry), to develop treatment options for PHTS. We will continue to manage a portfolio of projects to support ongoing research efforts into PHTS and establishing new partnerships. At a cellular level, the genetic alterations to the PTEN gene result in PHTS cause dysregulation of the PI3K/AKT/mTOR pathway. This pathway has been the subject of extensive scientific study because it is often abnormal in acquired (sporadic) cancers that occur in the general population. As result, it may be possible to repurpose inhibitors of the PI3K/AKT/mTOR pathway that were originally developed to treat common cancers to treat individuals with PHTS.

The Foundation carries out its objects by implementing activities that support delivery of its strategy as depicted in Figure 1.

Figure 1: The Foundation’s strategic goals & critical enabling activities

----- Start of picture text -----
Therapies for PHTS
prevention of cancer
Understanding
Partnerships
of PHTS Foundation
|L_|
Goals
----- End of picture text -----

Page 4

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

The central focus of our work is the development of therapy options for the non-malignant symptoms of PHTS that are clinically tractable and have a clear unmet need (Goal 1). In addition, the Foundation is increasingly focused on activities associated with PHTS and malignant disease (Goal 2).These include timely PHTS diagnosis to facilitate the initiation of cancer surveillance prior to a cancer diagnosis, as well as management of malignant disease when this occurs. Whilst continuing to be a longer-term aspiration of the Foundation, cancer prevention strategies are highly challenging at present.

Activities that are integral to ensuring the success of therapy development efforts, but not strategic goals per se, are detailed as ‘Enablers’. These encompass research efforts to improve understanding of both the biology of PTEN and PHTS, development of partnerships with key stakeholder groups, and development of a financially sustainable Foundation.

The work undertaken to fulfil the Foundation’s objectives in the field of PHTS may have beneficial effects that extend well beyond PHTS. In particular, basic scientific and clinical research aimed at understanding the pathobiology of cancer in PHTS may improve the understanding of cancers more generally.

Similarly, work on vascular anomalies, soft tissue overgrowth and hamartomas in PHTS, has the potential to benefit patients with other genetic disorders which predispose to these manifestations, as well as patients with sporadic non-syndromic conditions.

Also, in the field of neuroscience, there are several other neurodevelopmental conditions characterised by genetic mutations in cellular pathways that overlap with, or are linked to, the PI3K/AKT/mTOR pathway. These include TSC (caused by alterations in the TSC1 and TSC2 genes), Rett syndrome (caused by mutation in MECP2 ), and Fragile X syndrome (caused by transcriptional silencing of the FMR1 gene). Clinical and scientific knowledge gained in PHTS has the potential to support advancement in these related conditions and beyond, for example in non-syndromic ASD.

Finally, PHTS is a rare disease and conducting trials in rare diseases brings particular challenges. Approaches taken by the Foundation may help others who face similar issues. For example, the development of new and more efficient trial designs and disease-specific trial endpoints, partnering with pharmaceutical and biotech companies and contract research organisations (as well as academic collaborators), and early engagement with regulatory agencies, may provide paradigms for other charitable organisations working in rare diseases. The Foundation’s strategy, future plans, and budgets are annually reviewed and agreed by the trustees.

2. Activities undertaken in the year

The total expenditure for the year ended 31st March 2024 was £4,292,236. This expenditure supported implementation of the Foundation's objects as defined in the Articles of Association and further detailed in the Foundation’s strategy document. Expenditure was subject to initial approval by the Foundation’s board and subject to ongoing periodic review.

The total income received for the year ended 31st March 2024 was £681,591. This income was a result of the following activities:

3. Criteria used to assess the success of the reporting period

The Trustees meet at least once a quarter. A standing item of the board meetings is to assess the progress of the Foundation against its agreed annual goals, project progress as detailed in the Foundation’s dashboard and strategic objectives.

4. Review of significant activities undertaken to further charitable objectives for the public benefit

Statement of Confirmation

The Trustees confirm that they have given due consideration to the Charity Commission’s published guidance

Page 5

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

on the public benefit requirement under Charities Act 2011. They believe the development of therapy options for people with PHTS (the Foundation’s primary object) will alleviate significant unmet medical needs of people with PHTS as well as the high burden on healthcare systems associated with the condition, as is further explained in the overview below.

Overview: activities undertaken to further charitable objectives for the public benefit

The Foundation’s principal charitable objective is to protect and promote the health of individuals diagnosed with PTEN hamartoma tumour syndrome (PHTS) or other related conditions.

There were 21 active projects at the year-end, of which 19 were with academic collaborators and the rest with commercial partners. Several projects were in active development with 19 further having been previously completed. Since its inception, the work of the Foundation has been acknowledged in 47 peer reviewed academic research papers published in scientific journals. (A listing of publications may be found at https://www.ptenresearch.org/for-researchers-and-professionals/projects-and-publications/publications/) These activities have materially increased scientific knowledge associated with PHTS.

Significant progress was made on several key scientific projects:

Page 6

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

compound before year end; evaluation of our lead molecules will commence in 2025.

Governance:

A review of the Foundation’s constitution by a firm of charity-specialist solicitors led to revisions to its articles of association which were adopted by special resolution by the Foundation’s member on 18th July 2022. In addition, a new Trustee Policy of 4th November 2022 codified committees of the Board into the governance structure.

Processes for regular reporting and risk escalation to ensure transparent and informed decision-making continue to be used to guide the Foundation's grants and work. In the year to 31[st] March 2024, staff continued to report to and seek guidance and endorsement from the Trustees, at quarterly Board and Investment Committee meetings, and at Trustee Science meetings the latter being scheduled every two months.

Strategy:

The Foundation's strategy is continually refined and incrementally updated on the basis of emerging data and as previously noted, the team maintain and update the Five Year/Medium Term Plan highlighting key planned activities and goals for the coming years. A longer-term financial plan of activities to deliver the strategy is proactively maintained and costed for the period to March 2029, incorporating expenditure forecasts that are updated and revised on a six-monthly basis.

Staff:

As a result of the pandemic, the Foundation’s staff were required to transition to home-based working. Despite the restrictions being lifted, the Trustees and senior staff team have elected to retain this virtual working model as it not only reduces office rental costs but also allows access to a broader talent pool of staff free from geographical restrictions. Mindful of some of the potential downsides associated with permanent virtual working the senior staff team place significant value on maintaining regular face to team meetings and worked with an external facilitator to provide training and support to the team on leadership, engagement, roles and responsibilities and maximising productivity in a virtual environment.

Policies, Guidance Documents and Process:

The Foundation continues to maintain and develop policies and processes for HR, operations, financial awards and fundraising, as required.

Clinical Development Working Groups (CDWGs):

These are multidisciplinary groups of international PHTS thought leaders supporting the Foundation with outputs envisaged to play a key role in shaping and optimising the design of future prospective PHTS clinical, natural history and translational medicine studies with a goal of improving patient care more broadly. The continued development of the CDWGs over the last year has provided significant value to the Foundation.

Patient engagement:

The Foundation maintains regular interactions with patient advocacy groups. These include both dedicated meetings, a quarterly newsletter drafted in lay language and patient group presentations highlighting key Foundation activities on a periodic basis.

Page 7

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

Recognising the importance of soliciting important feedback from people with PHTS and their families as the community that the Foundation seeks to support, our research grant application process has been revised to ensure applicants not only provide details of how the proposed project will benefit the wider PHTS community of individuals with PHTS and their caregivers and families but also detail their interactions with PHTS patient organisations or other patient representatives in developing the application and how the feedback received has influenced the scope of the application. As noted in previous years the Foundation cannot offer specific advice to individual patients.

Analysis of publicly available scientific and medical literature:

Desk research continues to be undertaken on publications relating to the natural history and the mechanism of disease of PHTS. Staff team regularly review these developments to ensure the Foundation's activities remain relevant and robust. To maximise the value of this and as previously noted, the Foundation recently launched an online resource ‘PHTS Research Tools’ that includes information on patient cohorts, existing clinical trials data, and laboratory and animal models. It is hoped this will stimulate new ideas and drive further collaboration within the PHTS community, not only to improve the understanding of PHTS but also to accelerate future research. Resources included are generated both from our own funding activities as well those from other groups and funders to create as comprehensive a resource as possible.

Policy on grant and non-grant funding:

The Foundation provides grants in line with its strategic goals and mission.

The Foundation primarily funds research projects that can translate into better treatments and/or improved outcomes for people with PHTS. These include interventional clinical trials, natural history studies and patient registries, preclinical/translational research projects and, where appropriate, basic research projects.

Funding is primarily provided through two mechanisms:

Discussions arising from the Clinical Development Working Groups have also led to several grant applications.

Grants are awarded to Principal Investigators who have qualified with an MD or PhD and who have an established research programme in a recognised academic or clinical research institution. Eligibility is not restricted to any specific geography.

Funding is intended to support all essential costs relating to a project, including staff, consumables, equipment, travel and publication costs. The Foundation’s policy is to pay only those costs that are directly attributable to the activities of the grant.

Applications undergo a scientific, strategic, and programmatic assessment by the Foundation's internal research team. Successful applications at this stage are then generally submitted for external peer review by at least two independent subject matter experts. The peer-reviewed applications are then subject to review by the Scientific Advisory Board (SAB) prior to a final approval by trustees.

In addition to grants, the Foundation commissions work with industry partners including contract research organisations (CROs) in the pursuit of its mission. This contracted work undergoes a scientific, strategic and programmatic assessment by the Foundation's internal research team before work commences.

Fundraising:

The Foundation received £207 in donations (all restricted).

1. Use of volunteers

At present the Foundation does not utilise volunteer staff. As previously noted, trustees are engaged on a voluntary basis.

Page 8

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

2. Fundraising activities

The Foundation is primarily funded through one-off donations and income from its investments. The Foundation commissioned a fund-raising strategy paper from a professional charity fund-raising consultancy during the year but it is unlikely at the current time that professional fundraising will be pursued in the future.

When negotiating legal agreements, including grant terms and conditions, the Foundation actively seeks to equitably share with its academic and commercial partners any potential arising intellectual property ownership, commercialisation rights and/or royalties relative to the proportion of the total costs funded by the Foundation.

Further, by highlighting the unmet medical need of PHTS to pharmaceutical and biotech organisations coupled with potential regulatory incentives associated with both paediatric and rare disease drug development applicable to PHTS, we hope that such organisations may not only provide direct financial support to the charity to access preclinical models developed by the Foundation but also may independently support PHTS drug development.

Risk management:

We recognise the inherent risks associated with the development of therapy options for a rare disease such as PHTS given the complexity of the syndrome and low number of people with PHTS worldwide. In common with other organizations supporting drug development and life sciences, not all projects supported by the Foundation can be expected to have a positive outcome. However, negative outcomes can often inform our future strategy and provide valuable scientific data and learnings. Potential risks include, but are not limited to, the potential failure of preclinical studies and/or clinical trials to meet safety or efficacy endpoint criteria, the potential unwillingness of industrial partners to support PHTS development, and the challenges of meeting the requirements of global Health Authorities to ensure drug approvals in the rare disease setting.

In some cases, we will actively choose to undertake multiple activities in parallel to enhance the probability that we will ultimately fulfil our mission, as well as gate certain future activities on the read-out of predecessors. To ensure good stewardship of charitable funds the Foundation actively seeks the guidance of key opinion leaders in the PHTS field worldwide both via the SAB and the CDWGs. Further, grants continue to be independently peer reviewed, follow robust contracting procedures and are subject to active monitoring and evaluation by Foundation staff.

Whilst the immediate direct impact of the COVID-19 pandemic has largely passed, healthcare systems globally continue to report pressures in relation to catching up with clinical case backlogs and staffing issues resulting from the previous disruption. This has led to ongoing delays of certain clinical projects. We continue to monitor the situation closely in the context of ongoing and future planned activities with our key partners.

To enable active portfolio and risk management, the Foundation uses a project dashboard with visualisations of our portfolio of projects by phase, associated project risks, and financial analyses. It is acknowledged that, in the future, a more active approach to portfolio management will be needed, based not only on emerging data and which projects are most likely to lead to a future treatment for people with PHTS but which also considers the need for the Foundation to operate within its available funds. We utilise standard industry attrition rates of projects by phase to inform decision making and portfolio management and undertake a 6-monthly review of forecast of expected annual expenditure for the following 5-year period, in both fully loaded and attrition- adjusted models.

Potential risks also arise in relation to our finances. Though we have a generous endowment, our resources are finite. The Foundation has a bond portfolio whose constituents are held to maturity. The Foundation also had a growth investment portfolio (primarily comprising quoted equities) which was largely liquidated in June 2024, with some of the proceeds transferred to the bond portfolio and the balance invested in money market funds managed by JP Morgan. Together, these funds might reasonably be expected to cover expenditure to March 2029. Inflation continues to abate from its peak in Winter 2022; if there were a return to higher levels, however, the Foundation’s bond portfolio and liquid assets may fall short of the outgoings they are designed to fund.

The following other risks have been identified in our operational risk register and remedial action taken.

Page 9

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

replicate the Foundation’s data. In 2023, comprehensive cyber insurance was purchased after consultation with the Foundation’s insurance brokers.

Financial Review:

1. Review of the charity’s financial position as at the end of the reporting period

At the end of the reporting period the Foundation holds no restricted funds.

The Charity holds general funds of £23,741,548 at 31 March 2024, to be used for direct and support costs over the period to 31st March 2029.

2. Investment management

Brown Advisory continues to be engaged as the Foundation’s exclusive discretionary investment manager.

Brown Advisory have created a portfolio of bonds to be held to maturity, recently supplemented by the proceeds of liquidating a growth investment portfolio (largely comprising quoted equities) which together might reasonably be expected to cover forecast spend to March 2029. Of the investments managed on a discretionary basis for the Foundation by Brown Advisory, at least 85% must be realizable into cash within 5 business days; and up to a maximum 15% within 45 business days.

3. Reserves Policy and Going Concern

The Foundation does not implement a reserves policy.

All restricted and unrestricted donations received to date have been accounted for in the Foundation's accountancy software and are clearly split with respect to purpose and use.

With due regard to the Foundation’s finances and projected expenditure, the trustees remain satisfied that it has sufficient resources to continue as a going concern for at least 12 months after the approval of the financial statements to which this report relates.

4. Plans for Future Periods

In the coming year, the Foundation's existing granted and industry-based collaborations will continue to progress.

The Foundation will continue to forge links with members of the professional and patient communities, with the aim of facilitating future collaborative working. To this end, the Foundation intends to hold further scientific meetings including with its funded researchers and collaborators, and with industry collaborators and regulators such as the US FDA with the overall goal to enhance sharing of knowledge and promote synergy. Foundation staff will continue to participate in other events, meetings and patient days, where appropriate.

Trustees' Responsibilities Statement

The Trustees (who include all the directors of PTEN Research Foundation for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources,

Page 10

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

TRUSTEES’ REPORT FOR THE YEAR ENDED 31 MARCH 2024

including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to Auditors

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

In preparing this report, the Trustees have taken advantage of the small companies' exemption provided by section 415A of the Companies Act 2006.

This report was approved by the Trustees, on 4[th] December 2024 and signed on their behalf by:

Riccardo Zacconi

Trustee, PTEN Research Foundation

References

Page 11

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PTEN RESEARCH FOUNDATION

FOR THE YEAR ENDED 31 MARCH 2024

Opinion

We have audited the financial statements of PTEN Research Foundation (‘the charitable company’) for the year ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Page 12

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PTEN RESEARCH FOUNDATION

FOR THE YEAR ENDED 31 MARCH 2024

Opinions on other matters prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the course of our audit

Matters on which we are required to report by exception

In light of the knowledge and understanding of the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report included within the trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on page 10-11, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Page 13

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PTEN RESEARCH FOUNDATION

FOR THE YEAR ENDED 31 MARCH 2024

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team members. We then designed and performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion.

We obtained an understanding of the legal and regulatory frameworks within which the charitable company operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006, together with the Charities SORP (FRS102) 2019. We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company’s ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company for fraud.

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any. We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the override of controls by management. Our audit procedures to respond to these risks included enquiries of management, and the Audit Committee about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory correspondence with the Charity Commission and reading minutes of meetings of those charged with governance.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing noncompliance and cannot be expected to detect non-compliance with all laws and regulations.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Tara Westcott [ tarSigned7434BD51053E4A by:Westcott1...

Senior Statutory Auditor For and on behalf of: Crowe U.K. LLP, Statutory Auditor

4[th] Floor St James House, St James’ Square, Cheltenham. GL50 3PR Date: 17-Dec-24 | 15:43 GMT

Page 14

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2024

Note
Income from:
Donations
2
Investments
3
Total income
Expenditure on:
Raising funds
Charitable activities:
4,5
Direct costs
Support costs
Total expenditure
Net expenditure before net
(losses) on investments
Net (losses)/gains on investments
Foreign exchange gains/(losses)
on investments
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward		 Unrestricted
Funds
Restricted
funds
Total
funds
Total
funds
2024
£
2024
£
2024
£
2023
£
-
207
207
911
681,384
-
681,384
646,024
681,384
207
681,591
646,935
102,117
-
102,117
97,085
3,820,255
207
3,820,462
3,793,649
441,094
-
441,094
213,806
4,363,466
207
4,363,673
4,104,540
(3,682,082)
-
(3,682,082)
(3,457,605)
1,278,480
(254,196)
-
-
1,278,480
(254,196)
(1,217,732)
924,425
(2,657,798)
-
(2,657,798)
(3,750,912)
26,399,346
-
26,399,346
30,150,258
(2,657,798)
-
(2,657,798)
(3,750,912)
23,741,548
-
23,741,548
26,399,346

The notes on pages 18 to 33 form part of these financial statements.

Page 15

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

REGISTERED NUMBER: 10529899

BALANCE SHEET

AS AT 31 MARCH 2024

2024 2023
Note £ £
Fixed assets
Tangible assets 9 2,646 3,276
Investments 10 15,783,784 20,052,722
15,786,430 20,055,998
Current assets
Debtors 11 4,938 4,730
Investments 12 4,510,798 3,745,907
Cash at bank and in hand 3,828,592 3,828,592
 3,374,828
8,344,328 7,125,465 7,125,465
Creditors: amounts falling due within one
year 13 (389,210) (389,210) (782,117)
Net current assets 7,955,118 6,343,348
Net assets 23,741,548 26,399,346
Charity funds
Restricted funds 15 - -
Unrestricted funds 15 23,741,548 26,399,346
Total funds 23,741,548 26,399,346

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by (_ 53FBAEQB869949A...DocuSigned by: Riccardo Zacconi Trustee Date: 4[th] December 2024

The notes on pages 18 to 33 form part of these financial statements.

Page 16

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2024

Cash flows from operating activities
Note
Net cash provided by operating activities
17
Cash flows from investing activities
Purchase of tangible fixed assets
Proceeds from sale of investments
Purchase of investments
Investment income
Transfer to investments from cash
Net cash provided by/(used in) investing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents due to exchange rate movements
Cash and cash equivalents at the end of the year
2024
£
(4,754,430)
(1,698)
6,131,425
(1,400,703)
681,384
(184,978)
5,225,430
471,000
3,374,828
(17,236)
3,828,592		 2023
£
(3,615,695)
(1,249)
9,743,034
(5,691,644)
646,024
61,405
4,757,570
1,141,875
2,397,117
(164,164)
3,374,828

The notes on pages 18 to 33 form part of these financial statements

Page 17

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

1. Accounting policies

General information

PTEN Research Foundation is a charitable company limited by guarantee incorporated in England on 16 December 2016 and registered with the Charity Commission on 27 June 2017. Its registered office address is 4[th] Floor, St James House, St James Square, Cheltenham GL50 3PR.

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

PTEN Research Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. The accounts are prepared on the basis that the Charity is a going concern.

The accounts have been prepared in GBP sterling as this is the operating currency of the charity.

1.2 Company status

The sole member of the charity is Blue Compass PTC. In the event of the company being wound up, the liability in respect to the guarantee is limited to £1 per member of the charity.

1.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

Donations are recognised in the period in which they are pledged.

Gifts of investments are measured at fair value and are recognised on the balance sheet with a corresponding amount being recognised in income.

1.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Page 18

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

1. Accounting policies (continued)

Charitable activities are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include governance costs. All expenditure is inclusive of irrecoverable VAT. Accounting policies are supplemented by estimation techniques where judgement is required in measuring the value of income and expenditure.

Termination payments are recognised when the commitment is made to terminate employment.

1.6 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer equipment - 33% straight line

1.7 Investments

Current and fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading ‘Gains/(losses) on investments’ in the Statement of Financial Activities incorporating Income and Expenditure Account.

Fixed asset investments are those investments held for the generation of investment income, investment potential or both and have a maturity of at least one year from the balance sheet date.

Current asset investments are those investments held for investment purposes rather than to meet short term cash commitments as they fall due. Current asset investments are expected to be realised within 12 months of the reporting date and include cash on deposit and cash equivalents with a maturity of less than one year.

1.8 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.9 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments held to meet short term cash commitments as they fall due rather than for investment potential. Cash and short term highly liquid investments have a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Page 19

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

1. Accounting policies (continued)

1.10 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

Trade and other creditors are recognised at the settlement amount after any trade discounts received. Accruals are value based on the estimated amount to be paid.

1.11 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.12 Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities incorporating Income and Expenditure Account.

1.13 Pensions

The Charity operates a defined contribution pension scheme, and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

1.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Page 20

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

2. Income from donations

Unrestricted
funds 2024
Restricted
funds 2024
£
£
Donations
-
207
Restricted
funds 2023
£
Donations
911
3.
Investment income
Unrestricted
funds 2024
£
Investment income
681,384
Unrestricted
funds 2023
£
Investment income
646,024		 Total
funds
2024
£
207
Total
funds
2023
£
911
Total funds
2024
£
681,384
Total funds
2023
£
646,024

Page 21

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

4. Analysis of expenditure on charitable activities - summary by fund type

Charitable activities relating to clinical
trials and medical research
Charitable activities relating to clinical
trials and medical research
5.
Analysis of expenditure by activities
Charitable activities relating to
clinical trials and medical research
Charitable activities relating to
clinical trials and medical research		 Restricted
funds 2024
£
207
Restricted
funds 2023
£
911
Support
costs 2024
£
441,094
Support
costs 2023
£
213,806		 Total funds
2024
£
4,261,556
Total funds
2023
£
4,007,455







Total funds
2024
£
4,261,556
Activities undertaken
directly 2023
£
3,793,649		 Total funds
2023
£
4,007,455

These are costs incurred by the Foundation for its charitable purposes and comprise direct costs, which are attributable to a single charitable activity, and support costs, which are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources.

Page 22

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

5. Analysis of expenditure by activities (continued)

Analysis of direct costs

Staff Costs
Research contracts, grants, and other direct costs		 Activities 2024
£
491,537
3,328,925
3,820,462		 Total funds 2024
£
491,537
3,328,925
3,820,462

Staff costs comprise wages totalling £424,369 (2023 - £496,627), employers national insurance totalling £43,592 (2023 - £56,029) and pension costs totalling £23,576 (2023 - £26,509).

Activities 2023 Total funds 2023
£ £
Staff Costs 577,683 577,683
Research contracts, grants, and other direct costs 3,215,966 3,215,966
3,793,649 3,793,649

These direct costs are attributable to a single charitable activity.

Analysis of support costs

Staff Costs
Depreciation
Foreign exchange loss
General costs
Legal & professional fees
Bank charges
Premises costs
Travel costs
Audit fees (governance)
Loss on disposal of fixed assets		 Activities 2024
£
107,898
2,151
54,966
185,272
56,638
3,065
-
16,053
14,875
176
441,094		 Total funds 2024
£
107,898
2,151
54,966
185,272
56,638
3,065
-
16,053
14,875
176
441,094

Page 23

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

5. Analysis of expenditure by activities (continued)

Staff costs are made up of wages totalling £93,154 (2023 - £108,690), employers national insurance totalling £9,569 (2023 - £12,299) and pension costs totalling £5,175 (2023 - £5,819).

Staff Costs
Depreciation
Foreign exchange gain
General costs
Legal & professional fees
Bank charges
Travel costs
Audit fees (governance)		 Activities 2023
£
126,808
2,085
(6,931)
44,481
23,100
2,530
8,533
13,200
213,806		 Total funds 2023
£
126,808
2,085
(6,931)
44,481
23,100
2,530
8,533
13,200
213,806

These support costs are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources.

Page 24

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

6. Grants to Institutions

AstraZeneca
Biocruces Bizkaia Health Research Institute
Boston Children’s Hospital
Cambridge University
Charles River Laboratories International Inc.
Children’s Hospital of Philadelphia
Developmental Synaptopathies Consortium
Evotec International GmbH
Geisel School of Medicine
Generon Ltd.
Institut Josep Carreras
John Carroll University
Radboud University Medical Centre
Renown Health Foundation
Taconic Biosciences
The Cleveland Clinic
University of British Columbia
University College London
University Hospital Southampton NHS Foundation
University of Melbourne		 2024
£
-
-
186,627
5,557
1,474,141
51,218
-
949,240
97,264
15,600
45,355
7,894
-
38,187
62,525
50,401
29,910
219,743

23,605
-
3,257,267		 2023
£
56,978
1,755
85,618
5,557
773,812
-
47,003
1,556,022
34,417
-
64,776
70,886
65,704
83,246
-
41,350
-
311,033
8,729
(21,654)
3,185,232

During the year grants were made to institutions in respect of research projects and clinical trials.

These Grants to institutions form part of the Foundation’s direct costs, which are costs attributable to a single charitable activity.

Page 25

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

7. Auditors' remuneration

2024 2023
£ £
Fees payable to the Charity's auditor for the audit of the Charity's annual
accounts		 12,800 11,000
Fees payable to the Charity's auditor in respect of non-audit services 7,981 4,289
Auditor’s remuneration forms part of the Foundation’s support costs, which are not directly attributable to a
single charitable activity and are apportioned between charitable activities on a basis consistent with the
use of resources.

8. Staff costs

Wages and salaries
Social security costs
Other pension costs		 2024
£
521,857
53,161
24,417		 2023
£
605,643
68,328
32,328
599,435 706,299

Staff costs include direct costs, which are attributable to a single charitable activity, and support costs, which are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources.

Page 26

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION (A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

The average number of persons employed by the Charity during the year was as follows:

2024 2023
No. No.
Research and support staff 6 7

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

2024 2023
No. No.
In the band £70,001 - £80,000 2 2
In the band £80,001 - £90,000 - 1
In the band £90,001 - £100,000 1 -
In the band £110,001 - £120,000 - 1
In the band 170,001 - £180,000 1 1

Transactions with Trustees

During the year, expenses were reimbursed to 2 trustees (2023:2) totalling £3,482 (2023: £92). Expenses related to travel and IT costs (2023: travel costs).

Transactions with Key Management Personnel

During the year, the Charity's key management personnel received total remuneration of £435,834 (2023£528,710). Key management personnel comprised the Chief Executive and Director of Clinical Development, the Director of Translational Medicine, the Director of Research and the Director of Finance and Business Operations.

There were no termination payments made during the year, or the previous year.

Page 27

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

9. Tangible fixed assets

Cost or valuation
At 1 April 2023
Additions
Disposals
As at 31 March 2024
Depreciation
At 1 April 2023
Charge for the year
On Disposals
As at 31 March 2024
Net book value
At 31 March 2024
At 31 March 2023
10.
Fixed asset investments
Valuation
At 1 April 2023
Additions
Disposals
Revaluations
Transfers between classes
Foreign Exchange movement
At 31 March 2024		 Computer
equipment
£
7,214
1,698
(1,199)









Total
£
7,214
1,698
(1,199)
7,713 7,713
3,938
2,152
(1,023)		 3,938
2,152
(1,023)
5,067 5,067
2,646 2,646
3,276 3,276
Listed
Investments
£
20,052,722
1,300,991
(2,299,198)
1,143,930
(4,241,573)
(173,088)
15,783,784

Page 28

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

11. Debtors

Due within one year

2024 2023
£ £
Prepayments and accrued income 4,938 4,730

12. Current asset investments

Listed investments
13.
Creditors: Amounts falling due within one year
Trade creditors
Other creditors
Accruals
14.
Financial instruments
Financial assets
Financial assets measured at fair value through income and expenditure		 2024
£
4,510,798		 2022
£
3,745,907
2023
£
12,992
15,548
753,577
2024
£
23,454
6,565
359,191
389,210 782,117
2024
£
20,294,582		 2023
£
23,798,629

Financial assets measured at fair value through income and expenditure comprise of fixed and current asset investments.

Page 29

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

15. Statement of funds

Statement of funds - current year

Balance at Income Expenditure Gains/ Balance at
1 April 2023 (Losses) 31 March 2024
£ £ £ £ £
Unrestricted funds
General Funds 26,399,346 681,384 (4,363,466) 1,024,284 23,741,548
Restricted Funds
Medical Research - 207 (207) - -
Total 26,399,346 681,591 (4,363,673) 1,024,284 23,741,548
Medical Research- To support medical research taken place into the PTEN gene and finding a potential
treatment of PHTS.
Statement of funds – prior year
Balance at Income Expenditure Gains/ Balance at
1 April 2022 (Losses) 31 March 2023
£ £ £ £ £
Unrestricted funds
General Funds 30,150,258 646,024 (4,103,629) (293,307) 26,399,346
Restricted Funds
Medical Research - 911 (911) - -
Total 30,150,258 646,935 (4,104,540) (293,307) 26,399,346

Medical Research - To support medical research taken place into the PTEN gene and finding a potential treatment of PHTS.

Statement of funds – prior year

Page 30

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

16. Analysis of net assets between funds

Analysis of net assets between funds - current year

Tangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
Total
Analysis of net assets between funds - prior year
Tangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
Total		 Unrestricted
funds
2024
Unrestricted
funds
2023
£
£
2,646
15,783,784
8,344,328
(389,210)
23,741,548
3,276
20,052,722
7,125,465
(782,117)
26,399,346		 Total
funds
2024
£
2,646
15,783,784
8,344,328
(389,210)
23,741,548
Total
funds
2023
£
3,276
20,052,722
7,125,465
(782,117)
26,399,346

Page 31

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

17. Reconciliation of net movement in funds to net cash flow from operating activities

Net expenditure for the year (as per Statement of Financial
Activities)
Adjustments for:
Depreciation charges
Loss on disposal
Dividends and interests from investments
(Increase) in debtors
Increase/(Decrease) in creditors
Loss/(gain) on investments
Foreign exchange non-cash movements on investments
Net cash used in operating activities
18.
Analysis of cash and cash equivalents
Cash at bank
Total cash and cash equivalents		 2024
£
(2,657,798)
2,152
-
(681,384)
(208)
(392,908)
(1,278,480)
254,196
(4,754,430)
2024
£
3,828,592
3,828,592		 2023
£
(3,750,912)
2,065
-
(646,024)
(138)
486,007
1,217,732
(924,425)
(3,615,695)
2023
£
3,374,828
3,374,828

Page 32

Docusign Envelope ID: 248F0160-7326-4923-9253-E7A14443F7FF

PTEN RESEARCH FOUNDATION

(A company limited by guarantee)

NOTES ON FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

19. Analysis of changes in net debt

Cash at bank and in hand Liquid investments

At Cash Other non- At
1 April 2023 Flows cash 31 March 2024
changes
£ £ £ £
3,374,828 471,013 (17,249) 3,828,592
3,745,907 833,250 (68,359) 4,510,798
7,120,735 1,304,263 (85,608) 8,339,390

20. Pension commitments

The charity operates a defined contribution pension scheme, pension costs for the year were £80,927 (2023 - £76,403). At year end, a balance of £6,565 (2023: £15,546) was due to be paid in respect of pensions.

21. Related party transactions

In addition to the transactions disclosed in note 8, fees amounting to £52,633 (2023: £nil) were paid to Siriative Ltd., a UK limited company owned by Siriana Baldini, a Trustee, for legal services provided to the Foundation pursuant to a consultancy agreement approved by the Board. An amount of £14,400 was owed to Siriative Ltd. at 31[st] March 2024 (2023: £nil) and was included in trade creditors (Note 13).

Page 33